# scenario_002 Reviewer Summary

## Reviewer Takeaway

This run demonstrates a traceable protocol pre-review workflow for a synthetic Advanced or metastatic non-small cell lung cancer scenario. It identifies missing protocol details, compares public trial records, screens PubMed literature candidates, maps hospital data-readiness risks, and preserves safety boundaries.

Safety critic status: pass

## Scenario Scope

- intervention: PD-1/PD-L1 immune checkpoint inhibitor add-on therapy
- trial phase: Phase II
- primary endpoint: Progression-free survival.
- data boundary: synthetic scenario only; no real patient data and no EMR/HIS integration

## Main Pre-Review Risks

- **HIGH**: Study design, randomization, blinding, and comparator details are not specified. -> Clarify whether the study is randomized, blinded, placebo-controlled, active-comparator, or single-arm.
- **HIGH**: Performance status eligibility is not operationally defined. -> Define the accepted ECOG performance status range and how it will be documented.
- **HIGH**: Measurable disease requirement is not defined. -> Clarify whether measurable disease is required and which response assessment standard will be used.
- **HIGH**: Biomarker and molecular eligibility rules are unclear. -> Define required biomarker testing, exclusion rules, and how missing results will be handled.
- **MEDIUM**: Recruitment assumption is provided without feasibility rationale. -> Add screening pool, historical recruitment rate, or site feasibility evidence.
- **MEDIUM**: Follow-up visit attendance criterion needs an operational definition. -> Define required visit windows, acceptable missed visits, remote visit options, and how attendance feasibility will be assessed.

## Public Evidence Trace

- ClinicalTrials.gov retrieval status: success
- unique ClinicalTrials.gov records: 23
- PubMed retrieval status: success
- PubMed literature candidates: 14
- primary PubMed support candidates after manual screening: 5
- context-only candidates: 5
- excluded direct-support candidates: 4

Top ranked trial comparators:

- `NCT02846792` (10/10): Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer
- `NCT02848651` (10/10): A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer
- `NCT03023423` (10/10): A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
- `NCT03050060` (10/10): Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
- `NCT04105270` (10/10): RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

## Extracted Comparator Criteria

- `NCT02846792`: ECOG: performance status of 0; Timing: up to 16 months; Stage: stage IIIB, stage IV; Biomarker: mutations in epidermal growth factor receptor (EGFR), ALK) or ROS-1 are eligible provided they have progressed...
- `NCT02848651`: ECOG: performance status of 0; RECIST: RECIST v1.1; Timing: up to 32 months; Stage: Stage IIIB, metastatic; Biomarker: PD-L1) test result by immunohistochemistry (IHC) are eligible for the study * Partici, P...
- `NCT03023423`: ECOG: performance status of 0; Stage: metastatic, Stage IIIb; Biomarker: PD-L1) score of tumor cells (TC)1-3 and immune cell PD-L1 score of tumor-infiltrating
- `NCT03050060`: Timing: Up to 6 months, up to 2 years; Stage: stage IV, metastatic; Biomarker: PDL1 immune checkpoint inhibitor and nelfinavir as per standard of care * Ability
- `NCT04105270`: RECIST: RECIST 1.1; Stage: unresectable, stage IIIB; Biomarker: EGFR sensitizing (activating) mutation or ALK or ROS1 translocation, mutation * Measurable disease based on RECIST 1

## Accepted Literature Candidates

- PMID `38127362`: Compare treatment context, endpoints, safety monitoring, and eligibility structure.
- PMID `27718847`: Support follow-up questions on PD-L1 rules, prior therapy, endpoints, and safety capture.
- PMID `29658856`: Compare metastatic NSCLC endpoint framing and safety/AE monitoring expectations.
- PMID `30280635`: Use as a subtype-aware comparator, not as a universal NSCLC template.
- PMID `33894335`: Compare PFS/OS/response endpoint language and follow-up assumptions.

## Hospital Data-Readiness Signals

- total mapped items: 15
- high-risk items: 7
- items needing clarification: 11

High-risk or research-heavy data items:

- Molecular testing results such as EGFR, ALK, ROS1, and related actionable alterations. (pathology or molecular laboratory result)
- PD-L1 expression result where available. (pathology or molecular laboratory result)
- ECOG performance status. (clinician assessment or oncology research form)
- Baseline and follow-up CT imaging. (radiology report/images plus research response assessment)
- RECIST or tumor response assessment. (radiology report/images plus research response assessment)
- Informed consent documentation. (research consent documentation)

## Key Output Files

- `prototype/runs/scenario_002_run_001/final_report.md`
- `prototype/runs/scenario_002_run_001/top_trial_comparison.md`
- `prototype/runs/scenario_002_run_001/eligibility_criteria_extraction.json`
- `prototype/runs/scenario_002_run_001/pubmed_relevance_review.md`
- `prototype/runs/scenario_002_run_001/pubmed_manual_screening.json`
- `prototype/runs/scenario_002_run_001/data_readiness_table.md`

## Limitations

- This is not protocol approval, regulatory certification, medical advice, or patient eligibility determination.
- Regex and keyword extraction can miss or over-capture criteria.
- Public registry and PubMed records require human expert review before being used as evidence.
- Hospital data-readiness mapping is a planning aid and must be validated against the actual hospital system configuration.
